Articles

GLP-1 receptor agonists drive 25–40% of total weight loss from lean tissue — a ratio that directly suppresses resting energy expenditure. Growth hormone secretagogues counter this via the GH→IGF-1→mTOR axis, stimulating muscle protein synthesis and preferentially mobilising visceral adipose tissue. The mechanistic case is strong; RCT-level co-administration data remain limited as of 2026.

Seven peptides — BPC-157 (free base and acetate), KPV, TB-500, MOTS-C, Emideltide (DSIP), Semax, and Epitalon — are formally scheduled for Pharmacy Compounding Advisory Committee (PCAC) review on July 23–24, 2026. A favorable committee recommendation initiates the rulemaking pathway toward the FDA's 503A Bulk Drug Substances List, ending each substance's Category 2 restriction status.

In a caloric deficit, circulating IGF-1 drops ~40% and leucine's mTORC1 signal weakens due to reduced Sestrin2 displacement. IGF-1 LR3—engineered to evade IGF-binding proteins—maintains receptor-level PI3K/Akt input independently of energy status, while leucine supplies a parallel, lysosome-anchored RAGULATOR/Rag GTPase signal. The two inputs converge on mTORC1-S6K1/4E-BP1 through mechanistically distinct but additive routes.

During rapid GLP-1-driven weight loss, semaglutide creates a sustained caloric deficit that elevates muscle proteolysis — STEP 1 trial data show roughly 39–40% of total weight lost is lean mass. BPC-157 counters this via GH-receptor upregulation, VEGFR2-mediated angiogenesis, and satellite-cell activation, mechanistically targeting the same catabolic pathways GLP-1 agonists leave unaddressed.

A 2025 narrative review published in Current Reviews in Musculoskeletal Medicine (Springer) concludes that BPC-157 drives robust preclinical regeneration across tendon, ligament, muscle, and bone via at least three distinct molecular pathways — yet zero human RCTs exist, and its angiogenic signaling raises unresolved oncogenic questions that performance athletes and practitioners cannot currently quantify.